Eisai to Make New Investment in Expansion of Global Packaging Fa

Eisai to Make New Investment in Expansion of Global Packaging Facility at
Hatfield Production Plant in U.K. 
Tokyo, June 17, 2013 - (JCN Newswire) -  Eisai Co., Ltd. announced today that
it has decided to further invest at its Hatfield, Hertfordshire production
plant in the United Kingdom in creation of an additional packaging facility
ahead of plans to launch multiple new Eisai products. The Hatfield plant is
operated by the company's U.K. manufacturing subsidiary, Eisai
Manufacturing Ltd. 
The Hatfield plant serves as a global supply center for new products such as
antiepileptic agent Fycompa(R) while also functioning as a production and
packaging base for countries in Europe, where there is a demand for a high mix
of low-volume product presentations in multiple languages. The New Facility
will cover a total floor space of approximately 2,900 m2 and will be located
adjacent to the currently operating facility (total floor space: about 7,800
m2). Eisai plans to handle the packaging of its investigational anticancer
agent lenvatinib (generic name) at the New Facility and a packaging area for
handling highly potent compounds (total floor space: approximately 400 m2) will
be included at the site accordingly to comply with guidelines set out by the
Medicines and Healthcare Products Regulatory Agency (MHRA). Construction is
scheduled to begin in September 2013 and to be completed in mid-2014, with
launch of operations planned for September 2014. Eisai's investment in the
facility expansion will total approximately 8 million British pounds, with the
company forecasting a potential employee increase of up to 40 new permanent
personnel over the next five to seven years. 
Responding to today's expansion announcement, the Rt. Hon. David
Willetts, U.K. Minister of State for Universities and Science, Department for
Business, Innovation and Skills, welcomed the development: "Eisai's
decision to invest is great news for the U.K. and reflects the
Government's commitment to creating the best environment for life
sciences. It will build on the Hatfield site's manufacturing capability,
which I saw when I visited last year, and supports highly skilled jobs." 
Speaking on the decision, Eisai's President Haruo Naito comments:
"This new investment is a vote of confidence in our EMEA [Europe, Middle
East and Africa] Hatfield facility. The U.K. remains competitive as a location
for advanced manufacturing and I am delighted that we are now able to expand
our global center for packaging at Hatfield, home to our EMEA sales and
marketing, R&D and manufacturing operations." 
Eisai established the European Knowledge Centre (EKC), which integrates the
company's discovery research, clinical development, production, marketing,
and European headquarters functions into one site, in Hatfield, Hertfordshire
in 2009 with the aim of expanding its business operations in Europe. At
present, EKC plays an even more important role as the regional headquarters for
Eisai's EMEA business. Through this investment, the company aims to
strengthen its production functions, specifically in regard to its packaging
capacity at the Hatfield plant. In doing so, Eisai expects to continue to
enhance its presence in the EMEA region and thereby make further contributions
to patients on a global scale. 
About Eisai 
Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care
(hhc) company that discovers, develops and markets products throughout the
world. Eisai focuses its efforts in three therapeutic areas: integrative
neuroscience, including neurology and psychiatric medicines; integrative
oncology, which encompasses oncotherapy and supportive-care treatments; and
vascular/immunological reaction. Through a global network of research
facilities, manufacturing sites and marketing subsidiaries, Eisai actively
participates in all aspects of the worldwide healthcare system. For more
information about Eisai Co., Ltd., please visit www.eisai.com. 
Contact: 
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120 
Copyright 2013 JCN Newswire. All rights reserved. www.japancorp.net 
Provider ID: 00026898